Individual generic drug information

mifepristone

Reference monograph

Part of registered formulation

MIFEPRISTONE + MISOPROSTOL

Reference record: MIFEPRISTONE
Source: MSF Essential Drugs (January 2026)
Printed source pages: 219
Age groups indexed: Not recorded

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for MIFEPRISTONE only.

Therapeutic Action

Antiprogestogen

Source page 219

Indications

Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol

Source page 219

Safety

Extracted information for MIFEPRISTONE only.

Contraindications Adverse Effects Precautions

Do not administer to patients with chronic adrenal failure or severe uncontrolled asthma. May cause: gastrointestinal disturbances, vaginal bleeding, uterine contractions, headache. Breast-feeding: no contra-indication for a single dose; to be avoided if multiple doses

Source page 219

Dose and formulations

Extracted information for MIFEPRISTONE only.

Forms And Strengths

200 mg tablet

Source page 219

Dosage And Duration

200 mg single dose, followed by the administration of misoprostol 1 to 2 days later

Source page 219

Clinical care

Extracted information for MIFEPRISTONE only.

Remarks

Do not use mifepristone in ectopic or molar pregnancy.

Source page 219

Storage

– – Below 25 °C

Source page 219

Dose text by age group

Filter the extracted dose blocks for this individual drug.

No dose block was identified for this age filter. This does not establish whether the drug is suitable for that age group.

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

mifepristone

Reference monograph

Part of registered formulation

MIFEPRISTONE + MISOPROSTOL

Reference record: MIFEPRISTONE
Source: MSF Essential Drugs (January 2026)
Printed source pages: 219
Age groups indexed: Not recorded

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for MIFEPRISTONE only.

Therapeutic Action

Antiprogestogen

Source page 219

Indications

Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol

Source page 219

Safety

Extracted information for MIFEPRISTONE only.

Contraindications Adverse Effects Precautions

Source page 219

Dose and formulations

Extracted information for MIFEPRISTONE only.

Forms And Strengths

200 mg tablet

Source page 219

Dosage And Duration

200 mg single dose, followed by the administration of misoprostol 1 to 2 days later

Source page 219

Clinical care

Extracted information for MIFEPRISTONE only.

Remarks

Do not use mifepristone in ectopic or molar pregnancy.

Source page 219

Storage

– – Below 25 °C

Source page 219

Dose text by age group

Filter the extracted dose blocks for this individual drug.

No dose block was identified for this age filter. This does not establish whether the drug is suitable for that age group.

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.